Capital Raise
-
Senseonics Holdings, Inc. Closes Public Offering with Full Exercise of Underwriters’ Over-Allotment Option and Concurrent Private Placement
Senseonics Holdings raised $77.8 million via a public offering (115M shares at $0.50) and a $20.3M private placement from Abbott Laboratories, which acquired a 4.99% stake. The funds will accelerate U.S. commercialization of its Eversense 365, a 12-month implantable glucose monitor, and support innovation. While the capital extends operations through 2026, significant share dilution and low pricing reflect market skepticism. Abbott’s investment signals strategic interest in implantable CGM tech, despite maintaining dominance with its FreeStyle Libre system. Key challenges include securing Medicare coverage and expanding beyond niche medical markets.
